Vivek Subbiah, MD, serves as Chief, Early-Phase Drug Development joined Sarah Cannon Research Institute (SCRI) in 2023. In his role, Dr. Subbiah oversees SCRI’s nine drug development units and leads the expansion of early-phase capabilities and programs across SCRI’s growing research network of more than 1,300 physicians at more than 250 locations in 24 states. Previously, Dr. Vivek Subbiah was at the University of Texas MD Anderson Cancer Center where he was an associate professor in the Department of Investigational Cancer Therapeutics. During his near 15-year tenure there, Dr. Vivek Subbiah held several leadership roles including executive director, Medical Oncology Research, MD Anderson Cancer Network as well as clinical medical director, Division of Cancer Medicine where he oversaw both the outpatient and inpatient clinical care delivery operations for the Phase I program.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and lead the BRAF and RET tissue agnostic studies to FDA approval.  He has authored over 400 peer-reviewed publications in several high-impact journals such as The New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology, JAMA Oncology, Cancer Discovery, Lancet Oncology, Nature Reviews Clinical Oncology, Lancet Diabetes and Endocrinology, and Clinical Cancer Research.

After finishing his medical education in India, Dr. Vivek Subbiah completed a combined residency program in internal medicine and pediatrics at Case Western Reserve University, MetroHealth, Cleveland, Ohio. He received board-certifications in both internal medicine and pediatrics and completed fellowships in both adult and pediatric oncology at MD Anderson.

He is a member of the ESMO Translational Research and Precision Medicine Working Group and Annals of Oncology Editorial Board.